RU2008148901A - SUBSTITUTED ISOINDOLES AS YOUR INHIBITORS AND THEIR APPLICATION - Google Patents

Abstract

 1. The compound of formula I,! ! where R1 is selected from hydrogen, nitro, cyano, groups -Q-C1-6alkyl, -Q-C2-6alkenyl, -Q-C2-6alkynyl, -Q-C3-6cycloalkyl, -Q-C5-7cycloalkenyl, -Q-C1 -6alkylC3-6cycloalkyl, -Q-aryl, -Q-heteroaryl, -Q-C1-6alkylaryl, -Q-C1-6alkylheteroaryl, -Q-heterocyclyl and -Q-C1-6alkylheterocyclyl, wherein said -Q-C1-6alkyl, -Q-C2-6 alkenyl, -Q-C2-6 alkynyl, -Q-C3-6 cycloalkyl, -Q-C5-7 cycloalkenyl, -Q-C1-6 alkyl C3-6 cycloalkyl, -Q-aryl, -Q-heteroaryl, -Q- C1-6alkylaryl, -Q-C1-6alkylheteroaryl, -Q-heterocyclyl or -Q-C1-6alkylheterocyclyl optionally substituted with one, two or three R7; ! R2 is (C (R4) (R5)) nR6, C2-4 alkenyl R6, C2-4 alkynyl R6, C5-7 cycloalkenyl R6, nitro or cyano and, if n is greater than 1, then each C (R4) (R5) is independent of the others; ! R3 is independently selected from hydrogen, halogen, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, C5-7 cycloalkenyl, aryl, heteroaryl, heterocyclyl, C1-6 alkyl C3-6 cycloalkyl, C1-6 alkylaryl, C1-6 alkylheteroaryl and C1 -6alkylheterocyclyl, wherein said C1-6alkyl, C3-6alkenyl, C3-6alkynyl, C3-6cycloalkyl, C5-7cycloalkenyl, aryl, heteroaryl, heterocyclyl, C1-6alkylC3-6cycloalkyl, C1-6alkylaryl, C1-6alkylheteroaryl or C1-6alkylalkyl one, two or three A; ! -Q- is a direct bond, -CONH-, -CO-, -CON (C1-6alkyl) -, -CON (C3-6cycloalkyl) -, -SO-, -SO2-, -SO2NH-, -SO2N (C1 -6 alkyl) -, -SO2N (C3-6cycloalkyl) -, -NHSO2-, -N (C1-6alkyl) SO2-, -NHCO-, -N (C1-6alkyl) CO-, -N (C3-6cycloalkyl) CO - or -N (C3-6cycloalkyl) SO2-; ! R4 and R5 are independently selected from hydrogen, C1-6 alkyl, cyano, halo or nitro; or R4 and R5 together form oxo, C3-6cycloalkyl or heterocyclyl; ! R6 is selected from methyl, C3-6cycloalkyl, heterocyclyl, aryl and heteroaryl, where each specified methyl, C3-6cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally substituted by R7 in an amount of one d�

Claims (27)

1. The compound of formula I,

where R ¹ selected from hydrogen, nitro, cyano, groups -QC _1-6 alkyl, -QC _2-6 alkenyl, -QC _2-6 alkynyl, -QC _3-6 cycloalkyl, -Q-C _5-7 cycloalkenyl, - QC _1-6 alkyl C _3-6 cycloalkyl, -Q-aryl, -Q-heteroaryl, -QC _1-6 alkylaryl, -QC _1-6 alkylheteroaryl, -Q-heterocyclyl and -QC _1-6 alkylheterocyclyl, wherein said -QC _1-6 alkyl, -QC _2-6 alkenyl, -QC _2-6 alkynyl, -QC _3-6 cycloalkyl, -Q-C _5-7 cycloalkenyl, -QC _1-6 alkylC _3-6 cycloalkyl, -Q-aryl , -Q-heteroaryl, -QC _1-6 alkylaryl, -QC _1-6 alkylheteroaryl, -Q-heterocyclyl, or -QC _1-6 alkylheterocyclyl is optionally substituted with one, two or three R ^7; R ² represents (C (R ⁴⁾ (R ⁵⁾⁾ _n R ^6, C _2-4 alkenilR ^6, C _2-4 alkinilR ^6, C _5-7 tsikloalkenilR ^6, nitro or cyano and if n is greater than 1, then each C (R ⁴ ) (R ⁵ ) is independent of the others; R ^{3 is} independently selected from hydrogen, halogen, C _1-6 alkyl, C _3-6 alkenyl, C _3-6 alkynyl, C _3-6 cycloalkyl, C _5-7 cycloalkenyl, aryl, heteroaryl, heterocyclyl, groups C _1-6 alkylC _3-6 cycloalkyl, C _1-6 alkylaryl, C _1-6 alkylheteroaryl and C _1-6 alkylheterocyclyl, wherein said C _1-6 alkyl, C _3-6 alkenyl, C _3-6 alkynyl, C _3-6 cycloalkyl, C _5-7 cycloalkenyl, aryl, heteroaryl, heterocyclyl, C _1-6 alkylC _3-6 cycloalkyl, C _1-6 alkylaryl, C _1-6 alkylheteroaryl or C _1-6 alkylheterocyclyl is optionally substituted with one, two or three A; -Q- is a direct bond, -CONH-, -CO-, -CON (C _1-6 alkyl) -, -CON (C _3-6 cycloalkyl) -, -SO-, -SO ₂ -, -SO ₂ NH-, -SO ₂ N (C _1-6 alkyl) -, -SO ₂ N (C _3-6 cycloalkyl) -, -NHSO ₂ -, -N (C _1-6 alkyl) SO ₂ -, -NHCO- , —N (C _1-6 alkyl) CO—, —N (C _3-6 cycloalkyl) CO— or —N (C _3-6 cycloalkyl) SO ₂ -; R ⁴ and R ^{5 are} independently selected from hydrogen, C _1-6 alkyl, cyano, halo or nitro; or R ⁴ and R ⁵ together form oxo, C _3-6 cycloalkyl or heterocyclyl; R ⁶ is selected from methyl, C _3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each of said methyl, C _3-6 cycloalkyl, heterocyclyl, aryl and heteroaryl optionally substituted by R ⁷ in an amount of from one to four, and wherein any of the individual aryl or heteroaryl groups may optionally be fused to a 4-, 5-, 6- or 7-membered cycloalkyl, cycloalkenyl or heterocyclyl group to form a bicyclic ring system, wherein said bicyclic ring system is optionally substituted with A in an amount of one to four; R ^{7 is} independently selected from halogen, nitro, CHO, C _0-6 alkyl CN, OC _1-6 alkyl CN, C _0-6 alkyl OR ⁸ , OC _2-6 alkyl OR ⁸ , hydroxy, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy , C _0-6 alkilNR ⁸ R ^9, OC _2-6 alkilNR ⁸ R ^9, OC _2-6 alkilOC _2-6 alkilNR ⁸ R ^9, NR ⁸ OR ^9, C _0-6 alkilSO ₂ R ^8, OC _1-6 alkylCO ₂ R ⁸ , C _0-6 alkyl CONR ⁸ R ⁹ , OC _1-6 alkyl CONR ⁸ R ⁹ , OC _2-6 alkyl NR ⁸ (CO) R ⁹ , C _0-6 alkyl NR ⁸ (CO) R ⁹ , O (CO ) NR ⁸ R ⁹ , NR ⁸ (CO) OR ⁹ , NR ⁸ (CO) NR ⁸ R ⁹ , O (CO) OR ⁸ , O (CO) R ⁸ , C _0-6 alkyl COR ⁸ , OS _1-6 alkyl COR ⁸ , NR ⁸ (CO) (CO) R ⁸ , NR ⁸ (CO) (CO) NR ⁸ R ⁹ , C _0-6 alkyl SR ⁸ , C _0-6 alkyl (SO ₂ ) NR ⁸ R ⁹ , OC _{1- 6} alkyl NR ⁸ (SO ₂ ) R ⁹ , OC _0-6 alkyl (SO ₂ ) NR ⁸ R ⁹ , C _0-6 alkyl (SO) NR ⁸ R ⁹ , OC _1-6 alkyl (SO) NR ⁸ R ⁹ , OSO ₂ R ⁸ , SO ₃ R ⁸ , C _0-6 alkyl NR ⁸ (SO ₂ ) NR ⁸ R ⁹ , C _0-6 alkyl NR ⁸ (SO) R ⁹ , OC _2-6 alkyl NR ⁸ (SO) R ⁸ , OS _{1- 6} alkylSO ₂ R ⁸ , C _1-6 alkylSO ₂ R ⁸ , C _0-6 alkyl SOR ⁸ , C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _0-6 alkyl, C _3-6 cycloalkyl groups , C _0-6 alkylaryl, C _0-6 alkylheteroaryl, C _0-6 alkylheterocyclyl and OC _2-6 alkylheterocyclyl, wherein any C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _0-6 alkylC _3-6 cycloalkyl, C _0-6 alkylaryl, C _0-6 alkylheteroaryl, C _0-6 alkylheterocyclyl or OC _2-6 alkylheterocyclyl is optionally substituted with one or more R ¹⁴ and wherein any of the individual aryl or heteroaryl groups may optionally be the condensed ana with a 4-, 5-, 6- or 7-membered cycloalkyl, cycloalkenyl or heterocyclyl group to form a bicyclic ring system, where the bicyclic ring system is optionally substituted with A in an amount of one to four, provided that said bicyclic ring system is not the ring system of indane, benzo [1,3] dioxole or 2,3-dihydrobenzo [1,4] dioxin; R ^{14 is} selected from halogen, nitro, CHO, C _0-6 alkyl CN, OS _1-6 alkyl CN, C _0-6 alkyl OR ⁸ , OS _1-6 alkyl OR ⁸ , fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C _{0 -6} alkilNR ⁸ R ^9, OC _2-6 alkilNR ⁸ R ^9, OC _2-6 alkilOS _2-6 alkilNR ⁸ R ^9, NR ⁸ OR ^9, C _0-6 alkilSO ₂ R ^8, OC _1-6 alkilSO ₂ R ⁸ , C _0-6 alkylCONR ⁸ R ⁹ , OC _1-6 alkylCONR ⁸ R ⁹ , OC _2-6 alkylNR ⁸ (CO) R ⁹ , C _0-6 alkylNR ⁸ (CO) R ⁹ , O (CO) NR ⁸ R ⁹ , NR ⁸ (CO) OR ⁹ , NR ⁸ (CO) NR ⁸ R ⁹ , O (CO) OR ⁸ , O (CO) R ⁸ , C _0-6 alkyl COR ⁸ , OS _1-6 alkyl COR ⁸ , NR ⁸ (CO) (CO) R ⁸ , NR ⁸ (CO) (CO) NR ⁸ R ⁹ , C _0-6 alkyl SR ⁸ , C _0-6 alkyl (SO ₂ ) NR ⁸ R ⁹ , OC _2-6 alkyl NR ⁸ (SO ₂ ) R ⁹ , OC _0-6 alkyl (SO ₂ ) NR ⁸ R ⁹ , C _0-6 alkyl (SO) NR ⁸ R ⁹ , OC _1-6 alkyl (SO) NR ⁸ R ⁹ , OSO ₂ R ⁸ , SO ₃ R ⁸ , C _{0 -6} AlkylNR ⁸ (SO ₂ ) NR ⁸ R ⁹ , C _0-6 AlkylNR ⁸ (SO) R ⁹ , OC _2-6 alkylNR ⁸ (SO) R ⁸ , OC _1-6 alkylSO ₂ R ⁸ , C _1-6 alkilSO ₂ R ^8, C _0-6 alkilSOR ^8, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl groups, C _0-6 alkylC _3-6 cycloalkyl, C _0-6 alkylaryl, C _{0- 6} alkylheteroaryl, C _0-6 alkylheterocyclyl and OC _2-6 alkylheterocyclyl, wherein said C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _0-6 alkylC _3-6 cycloalkyl, C _0-6 alkylaryl, , C _0-6 alkyl heteroaryl, C _0-6 alkyl heterocyclyl or OC _2-6 alkyl heterocyclyl optionally substituted with A in an amount of one to four; R ⁸ and R ^{9 are} independently selected from hydrogen, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, C _0-6 alkyl, C _3-6 cycloalkyl groups , C _0-6 alkylaryl, C _0-6 alkylheteroaryl, C _0-6 alkylheterocyclyl and C _1-6 alkilNR ¹⁰ R ¹¹ where said C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _{0 -6} alkylC _3-6 cycloalkyl, C _0-6 alkylaryl, C _0-6 alkylheteroaryl or C _0-6 alkylheterocyclyl a is optionally substituted with from one to four; or R ⁸ and R ⁹ together can form a 4-6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which is optionally substituted with A; whenever two R ⁸ groups are in a given structure, they may possibly together form a 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which is optionally substituted with A; R ¹⁰ and R ¹¹ are independently selected from hydrogen, C _1-6 alkyl, C _3-6 alkenyl, C _3-6 alkynyl groups, C _0-6 alkylC _3-6 cycloalkyl, C _0-6 alkylaryl, C _0-6 alkylheterocyclyl and C _0-6 alkylheteroaryl, wherein said C _1-6 alkyl, C _3-6 alkenyl, C _3-6 alkynyl, C _0-6 alkylC _3-6 cycloalkyl, C _0-6 alkylaryl, C _0-6 alkylheteroaryl or C _0-6 alkylheterocyclyl optionally substituted with A; or R ¹⁰ and R ¹¹ together can form a 4-6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, optionally substituted with A; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; And independently selected from oxo, halogen, nitro, CN, OR ¹² , C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, groups C _0-6 alkylaryl, C _0-6 alkyl heteroaryl, C _0-6 alkyl C _3-6 cycloalkyl, C _0-6 alkyl heterocyclyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, OS _2-6 alkyl NR ¹² R ¹³ , NR ¹² R ¹³ , CONR ¹² R ¹³ , NR ¹² (CO) R ¹³ , O (CO) C _1-6 alkyl, (CO) OS _1-6 alkyl, COR ¹² , (SO ₂ ) NR ¹² R ¹³ , NSO ₂ R ¹² , SO ₂ R ¹² , SOR ¹² , (CO) C _{1 -6} alkyl NR ¹² R ¹³ , (SO ₂ ) C _1-6 alkyl NR ¹² R ¹³ , OSO ₂ R ¹² and SO ₃ R ¹² , wherein said C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, C _0-6 alkylaryl, C _0-6 alkylheteroaryl, C _0-6 alkylheterocyclyl or C _0-6 alkylC _3-6 tsikloa keel optionally substituted by halo, OSO ₂ R ^12, SO ₃ R ^12, nitro, cyano, OR ^12, C _1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy or trifluoromethoxy; R ¹² and R ^{13 are} independently selected from hydrogen, C _1-6 alkyl, C _3-6 cycloalkyl, aryl, heteroaryl, and heterocyclyl, wherein said C _1-6 alkyl, C _3-6 cycloalkyl, aryl, heteroaryl, or heterocyclyl is optionally substituted with one two or three hydroxy, cyano, halo or C _1-3 alkyloxy; or R ¹² and R ¹³ together can form a 4-6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, optionally substituted with hydroxy, C _1-3 alkyloxy, cyano or halo; provided that the following compounds are excluded: 3-amino-1-cyano-N-phenyl-1H-isoindole-1-carboxamide; 3-amino-1- (1H-benzimidazol-2-yl) -1H-isoindole-1-carbonitrile; 4.4 '- (3-amino-1H-isoindole-1,1-diyl) diphenol; 1-phenyl-1H-isoindole-3-amine; 1-methyl-1H-isoindol-3-amine; 1,1-dimethyl-1H-isoindole-3-amine; 2- [3-amino-1- (4-hydroxyphenyl) -1H-isoindol-1-yl] phenol; in the form of a free base or a pharmaceutically acceptable salt, solvate or solvate thereof. 2. The compound according to claim 1, where R ⁸ and R ^{9 are} independently selected from hydrogen, C _1-6 alkyl, C _2-6 alkenyl, C _2-6 alkynyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, groups C _0-6 alkylC _3-6 cycloalkyl, C _0-6 alkylaryl, C _0-6 alkylheteroaryl, C _0-6 alkylheterocyclyl and C _1-6 alkilNR ¹⁰ R ¹¹ where said C _1-6 alkyl, C _2-6 alkenyl , C _2-6 alkynyl, C _0-6 alkylC _3-6 cycloalkyl, C _0-6 alkylaryl, C _0-6 alkylheteroaryl or C _0-6 alkylheterocyclyl is optionally substituted by A; or R ⁸ and R ⁹ together can form a 4-6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which is optionally substituted with A; whenever two R ⁸ groups are in a given structure, they can possibly together form a 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S, which is optionally substituted with A. 3. The compound according to claim 1, where the following compounds are excluded: 3-methyl-3-phenylisoindolin-1-imine; 3 '- (3-methyl-2,3-dihydro-1H-isoindol-1-yl) biphenyl-3-carbonitrile; 3- (3'-methoxybiphenyl-3-yl) -3-methylisoindolin-1-imine; 3- (3'-chlorobiphenyl-3-yl) -3-methylisoindolin-1-imine; and 3-methyl-3- (3-pyridin-3-ylphenyl) isoindolin-1-imine; in the form of a free base or a pharmaceutically acceptable salt, solvate or solvate thereof. 4. The compound according to any one of claims 1 to 3, where R ^{1 is} selected from —Q-aryl and -Q-heteroaryl, wherein said —Q-aryl and —Q-heteroaryl are optionally substituted with one, two, or three R ⁷ ; R ² represents (C (R ⁴ ) (R ⁵ )) _n R ⁶ , and if n is greater than 1, then each C (R ⁴ ) (R ⁵ ) is independent of the others; R ^{3 is} independently selected from hydrogen, halogen, C _1-6 alkyl, C _3-6 alkenyl, C _3-6 alkynyl, C _3-6 cycloalkyl, C _5-7 cycloalkenyl, aryl, heteroaryl, heterocyclyl, groups C _1-6 alkylC _3-6 cycloalkyl, C _1-6 alkylaryl, C _1-6 alkylheteroaryl or C _1-6 alkylheterocyclyl, wherein C _1-6 alkyl, C _3-6 alkenyl, C _3-6 alkynyl, C _3-6 cycloalkyl, C _5-7 cycloalkenyl, aryl, heteroaryl, heterocyclyl, C _1-6 alkyl C _3-6 cycloalkyl, C _1-6 alkylaryl, C _1-6 alkylheteroaryl or C _1-6 alkylheterocyclyl optionally substituted with one, two or three A; -Q- is a direct bond; R ⁴ and R ^{5 are} independently selected from hydrogen, C _1-6 alkyl, cyano, halo or nitro; or R ⁴ and R ⁵ together form oxo, C _3-6 cycloalkyl or heterocyclyl; R ^{6 is} selected from aryl or heteroaryl, where each of said aryl or heteroaryl is optionally substituted with R ⁷ in an amount of one to four, and where any of the individual aryl or heteroaryl groups may possibly be fused to 4-, 5-, 6- or 7 a membered cycloalkyl, cycloalkenyl or heterocyclyl group to form a bicyclic ring system; R ⁷ is independently selected from halo, C _0-6 alkilOR ^8, hydroxy, OSO ₂ R ^8, C _1-6 alkyl groups, C _0-6 alkylaryl and C _0-6 alkylheteroaryl, wherein any C _1-6 alkyl, C _{0 -6} alkylaryl and C _0-6 alkylheteroaryl may optionally be substituted with one or more R ¹⁴ ; R ^{14 is} selected from halogen, OSO ₂ R ⁸ and C _0-6 alkyl OR ⁸ , R ^{8 is} independently selected from hydrogen, C _1-6 alkyl, and trifluoromethyl. 5. The compound according to any one of claims 1 to 3, where R ¹ represents —Q-aryl, wherein said —Q-aryl is optionally substituted with one, two or three R ⁷ ; R ² represents (C (R ⁴ ) (R ⁵ )) _n R ⁶ ; -Q- is a direct bond; R ⁶ is aryl, which is optionally substituted with R ⁷ in an amount of one to four, and where an individual aryl group may optionally be fused to a 4-, 5-, 6- or 7-membered heterocyclyl group to form a bicyclic ring system; R ⁷ is independently selected from halo, C _0-6 alkilOR ^8, hydroxy, OSO ₂ R ^8, C _1-6 alkyl groups, C _0-6 alkylaryl and C _0-6 alkylheteroaryl, wherein any C _1-6 alkyl, C _{0 -6} alkylaryl and C _0-6 alkylheteroaryl may optionally be substituted with one or more R ¹⁴ ; R ^{14 is} selected from halogen, OSO ₂ R ⁸ and C _0-6 alkyl OR ⁸ , R ^{8 is} independently selected from hydrogen, C _1-6 alkyl and trifluoromethyl; m is 0; n is 0. 6. The compound according to any one of claims 1 to 3, where R ^{1 is} selected from —Q-aryl and -Q-heteroaryl, wherein said —Q-aryl and —Q-heteroaryl are optionally substituted with one, two, or three R ⁷ ; R ² represents (C (R ⁴ ) (R ⁵ )) _n R ⁶ ; R ³ represents halogen; -Q- is a direct bond; R ^{6 is} selected from aryl and heteroaryl, wherein said aryl and heteroaryl is optionally substituted with R ⁷ in an amount of one to four; R ⁷ is independently selected from halo, C _0-6 alkilSN, C _0-6 alkilOR ^8, trifluoromethyl, trifluoromethoxy, C _0-6 alkylaryl groups and C _0-6 alkylheteroaryl, wherein said C _0-6 alkylaryl or C _0-6 alkylheteroaryl optionally substituted with one or more R ¹⁴ ; R ^{14 is} selected from halogen, CHO, C _0-6 alkyl CN, C _0-6 alkyl OR ⁸ , C _0-6 alkylCONR ⁸ R ⁹ , (CO) R ⁹ and C _1-6 alkyl; R ⁸ and R ^{9 are} independently selected from hydrogen, C _1-6 alkyl; m is 0 or 1; and n is 0. 7. The compound according to any one of claims 1 to 3, where R ¹ represents —QC _1-6 alkyl; R ² represents (C (R ⁴ ) (R ⁵ )) _n R ⁶ ; -Q- is a direct bond; R ⁶ is aryl, wherein said aryl is optionally substituted with one or two R ⁷ ; R ^{7 is} independently selected from halogen, C _0-6 alkyl CN, C _0-6 alkyl OR ⁸ , C _0-6 alkylaryl and C _0-6 alkyl heteroaryl groups, wherein said C _0-6 alkylaryl or C _0-6 alkylheteroaryl is optionally substituted with one or more than R ¹⁴ ; R ^{14 is} selected from halogen, C _0-6 alkyl CN and C _0-6 alkyl OR ⁸ ; R ⁸ represents C _1-6 alkyl; m is 0; and n is 0. 8. The compound according to claim 1, where R ¹ represents —Q-aryl substituted with one or two R ⁷ ; R ² represents (C (R ⁴ ) (R ⁵ )) _n R ⁶ ; -Q- is a direct bond; R ^{6 is} selected from aryl and heteroaryl, wherein said aryl and heteroaryl is optionally substituted with R ⁷ in an amount of one to four; R ^{7 is} independently selected from halogen, trifluoromethyl, OSO ₂ R ⁸ , C _0-6 alkyl OR ⁸ , C _1-6 alkyl, C _0-6 alkylaryl and C _0-6 alkylheteroaryl groups, where any C _0-6 alkylaryl or C _{0 -6} alkyl heteroaryl is optionally substituted with one or more R ¹⁴ ; R ^{14 is} selected from halogen, C _0-6 alkyl CN and C _0-6 alkyl OR ⁸ ; R ^{8 is} selected from C _1-6 alkyl, trifluoromethyl, C _0-6 alkylaryl and C _0-6 alkylheteroaryl groups, wherein said C _0-6 alkylaryl, or C _0-6 alkylheteroaryl, or C _0-6 alkylheterocyclyl is optionally substituted with A an amount of one to four; m is 0; n is 0; A is selected from halogen and C _1-6 alkyl. 9. The compound according to claim 1, where R ¹ represents —Q-aryl substituted with one or two R ⁷ ; R ² represents (C (R ⁴ ) (R ⁵ )) _n R ⁶ ; -Q- is a direct bond; R ⁶ is aryl substituted with R ⁷ in an amount of one to four; R ^{7 is} independently selected from halogen, OSO ₂ R ⁸ , C _0-6 alkyl OR ⁸ , C _1-6 alkyl, C _0-6 alkylaryl and C _0-6 alkyl heteroaryl groups, where any C _0-6 alkylaryl or C _0-6 alkyl heteroaryl is optionally substituted with one or more R ¹⁴ ; R ^{14 is} selected from halogen, C _0-6 alkyl CN and C _0-6 alkyl OR ⁸ ; R ^{8 is} selected from C _1-6 alkyl, trifluoromethyl, C _0-6 alkylaryl and C _0-6 alkylheteroaryl groups, wherein said C _0-6 alkylaryl, or C _0-6 alkylheteroaryl, or C _0-6 alkylheterocyclyl is optionally substituted with A an amount of one to four; m is 0; n is 0; A is selected from halogen and C _1-6 alkyl. 10. The compound according to claim 1, where R ¹ represents —Q-aryl substituted with one or two R ⁷ ; R ² represents (C (R ⁴ ) (R ⁵ )) _n R ⁶ ; -Q- is a direct bond; R ⁶ is heteroaryl, optionally substituted with R ⁷ in an amount of one to four; R ^{7 is} independently selected from halogen, OSO ₂ R ⁸ , C _0-6 alkyl OR ⁸ , C _1-6 alkyl, C _0-6 alkylaryl and C _0-6 alkylheteroaryl groups, where any C _{0-6 is} alkylaryl or C _0-6 alkyl heteroaryl is optionally substituted with one or more R ¹⁴ ; R ^{14 is} selected from halogen, C _0-6 alkyl CN and C _0-6 alkyl OR ⁸ ; R ^{8 is} selected from C _1-6 alkyl, trifluoromethyl, C _0-6 alkylaryl and C _0-6 alkylheteroaryl groups, wherein said C _0-6 alkylaryl, or C _0-6 alkylheteroaryl, or C _0-6 alkylheterocyclyl is optionally substituted with A an amount of one to four; m is 0; n is 0; A is selected from halogen and C _1-6 alkyl. 11. A compound selected from: 3,3-disrenyl-3H-isoindol-1-ylamine; 3- (3'-methoxybiphenyl-3-yl) -3- (4-methoxyphenyl) -3H-isoindol-1-ylamine trifluoroacetate; trifluoromethanesulfonic acid 5- [3-amino-1- (4-methoxyphenyl) -1H-isoindol-1-yl] -3'-methoxybiphenyl-2-yl ester trifluoroacetate; 5- [3-amino-1- (4-methoxyphenyl) -1H-isoindol-1-yl] -3'-methoxybiphenyl-2-ol trifluoroacetate; 4,4 '- (3-aminoisoindole-1,1-diyl) bis-phenol; 4- [3-amino-1- (4-methoxyphenyl) -1H-isoindol-1-yl] -2-pyridin-3-ylphenol trifluoroacetate; 4- [3-amino-1- (4-methoxyphenyl) -1H-isoindol-1-yl] -2-pyrimidin-5-ylphenol trifluoroacetate; 3- (4-methoxyphenyl) -3- (3-pyridin-3-ylphenyl) -3H-isoindol-1-ylamine trifluoroacetate; 3- [3- (2-fluoropyridin-3-yl) phenyl] -3- (4-methoxyphenyl) -3H-isoindol-1-ylamine trifluoroacetate; 3- (3-bromophenyl) -3- (4-methoxyphenyl) -3H-isoindol-1-ylamine; 3- (4-methoxyphenyl) -3- [3- (5-methoxypyridin-3-yl) phenyl] -3H-isoindol-1-ylamine trifluoroacetate; 3- (4-methoxyphenyl) -3- (3-pyrimidin-5-ylphenyl) -3H-isoindol-1-ylamine trifluoroacetate; methanesulfonic acid 3 '- [3-amino-1- (4-methoxyphenyl) -1H-isoindol-1-yl] -5-methoxybiphenyl-3-yl ester trifluoroacetate; 3- (2,3-dihydrobenzo [b] [1,4] dioxin-6-yl) -3- (3- (2-fluoropyridin-3-yl) phenyl) -3H-isoindole-1-amine trifluoroacetate; 3- (2,3-dihydrobenzo [b] [1,4] dioxin-6-yl) -3- (3- (5-methoxypyridin-3-yl) phenyl) -3H-isoindole-1-amine trifluoroacetate; 3- (2,3-dihydrobenzo [b] [1,4] dioxin-6-yl) -3- (3- (pyridin-3-yl) phenyl) -3H-isoindole-1-amine trifluoroacetate; 3- (2,3-dihydrobenzo [b] [1,4] dioxin-6-yl) -3- (3- (pyrimidin-5-yl) phenyl) -3H-isoindole-1-amine trifluoroacetate; 3- (3'-methoxybiphenyl-3-yl) -3- (4-methoxy-3-methylphenyl) -3H-isoindol-1-ylamine trifluoroacetate; 3- (4-methoxy-3-methylphenyl) -3- [3- (5-methoxypyridin-3-yl) phenyl] -3H-isoindol-1-ylamine trifluoroacetate; 3- (4-methoxy-3-methylphenyl) -3- (3-pyridin-3-ylphenyl) -3H-isoindol-1-ylamine trifluoroacetate; 3- (4-methoxy-3-methylphenyl) -3- (3-pyrimidin-5-ylphenyl) -3H-isoindol-1-ylamine trifluoroacetate; 3- [3- (2-fluoropyridin-3-yl) phenyl] -3- (4-methoxy-3-methylphenyl) -3H-isoindol-1-ylamine trifluoroacetate; methanesulfonic acid 3 '- [3-amino-1- (4-methoxy-3-methylphenyl) -1H-isoindol-1-yl] -5-methoxybiphenyl-3-yl ester trifluoroacetate; 5 '- (3-amino-1- (2,3-dihydrobenzo [b] [1,4] dioxin-6-yl) -1H-isoindol-1-yl) -5-methoxybiphenyl-3-yl-methanesulfonate trifluoroacetate ; 3- (2,3-dihydrobenzo [b] [1,4] dioxin-6-yl) -3- (3'-methoxybiphenyl-3-yl) -3H-isoindole-1-amine trifluoroacetate; 3-benzo [1,3] dioxol-5-yl-3- (3-pyridin-3-yl) -3H-isoindol-1-ylamine trifluoroacetate; 3-benzo [1,3] dioxol-5-yl-3- (3-bromophenyl) -3H-isoindol-1-ylamine; 3-benzo [1,3] dioxol-5-yl-3- (3-pyrimidin-5-yl-phenyl) -3H-isoindol-1-ylamine trifluoroacetate; 3-benzo [1,3] dioxol-5-yl-3- [3- (2-fluoropyridin-3-yl) phenyl] -3H-isoindol-1-ylamine trifluoroacetate; 3-benzo [1,3] dioxol-5-yl-3- [3- (5-methoxypyridin-3-yl) phenyl] -3H-isoindol-1-ylamine trifluoroacetate; in the form of a free base or a pharmaceutically acceptable salt, solvate or solvate thereof. 12. A compound selected from: 3-benzo [1,3] dioxol-5-yl-3- (3'-methoxybiphenyl-3-yl) -3H-isoindol-1-ylamine trifluoroacetate; methanesulfonic acid 3 '- (3-amino-1-benzo [1,3] dioxol-5-yl-1H-isoindol-1-yl) -5-methoxybiphenyl-3-yl ester trifluoroacetate; 4- [3-amino-1- (3-pyridin-3-ylphenyl) -1H-isoindol-1-yl] phenyl ester trifluoroacetate methanesulfonic acid; 4- [3-amino-1- (3-bromophenyl) -1H-isoindol-1-yl] phenyl ether trifluoroacetate methanesulfonic acid; 4- {3-amino-1- [3- (2-fluoropyridin-3-yl) phenyl] -1H-isoindol-1-yl} phenyl ester trifluoroacetate methanesulfonic acid; 4- [3-amino-1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-1-yl] phenyl ether trifluoroacetate methanesulfonic acid; 4- {3-amino-1- [3- (5-methoxypyridin-3-yl) phenyl] -1H-isoindol-1-yl} phenyl ether trifluoroacetate methanesulfonic acid; 4- [3-amino-1- (3'-methoxybiphenyl-3-yl) -1H-isoindol-1-yl] phenyl ether trifluoroacetate methanesulfonic acid; methanesulfonic acid 4- [3-amino-1- (5'-methanesulfonyloxy-3'-methoxybiphenyl-3-yl) -1H-isoindol-1-yl] phenyl ether trifluoroacetate; 3- [3- (2-fluoropyridin-3-yl) phenyl] -3-pyridin-4-yl-3H-isoindol-1-ylamine trifluoroacetate; 3-pyridin-4-yl-3- (3-pyridin-3-ylphenyl) -3H-isoindol-1-ylamine trifluoroacetate; 3-pyridin-4-yl-3- (3-pyrimidin-5-ylphenyl) -3H-isoindol-1-ylamine trifluoroacetate; 3- [3- (5-methoxypyridin-3-yl) phenyl] -3-pyridin-4-yl-3H-isoindol-1-ylamine trifluoroacetate; 3- (3'-methoxybiphenyl-3-yl) -3-pyridin-4-yl-3H-isoindol-1-ylamine trifluoroacetate; 3- {3- [3-amino-1- (4-methoxyphenyl) -1H-isoindol-1-yl] phenyl} thiophene-2-carbaldehyde 1.5 acetate; 4- [3-amino-1- (3-bromophenyl) -1H-isoindol-1-yl] benzonitrile; 1- [3- (1-isobutyl-1H-pyrazol-4-yl) phenyl] -1- (4-methoxyphenyl) -1H-isoindol-3-amine 0.5 acetate; 1- (4-methoxyphenyl) -1- [3- (5-methyl-2-furyl) phenyl] -1H-isoindol-3-amine 0.5 acetate; 3 '- [3-amino-1- (4-methoxyphenyl) -1H-isoindol-1-yl] biphenyl-2-carboxamide 0.5 acetate; 1- [3- (5-fluoropyridin-3-yl) phenyl] -1- [4- (trifluoromethoxy) phenyl] -1H-isoindol-3-amine 0.75 acetate; 1- (3-pyrimidin-5-ylphenyl) -1- [4- (trifluoromethoxy) phenyl] -1H-isoindol-3-amine 0.25 acetate; 4- [3-amino-1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-1-yl] benzonitrile 0.25 acetate; 1- [3- (5-fluoropyridin-3-yl) phenyl] -1- [4- (trifluoromethyl) phenyl] -1H-isoindol-3-amine 0.25 acetate; 1- (3-pyrimidin-5-ylphenyl) -1- [4- (trifluoromethyl) phenyl] -1H-isoindol-3-amine 0.25 acetate; 3- [3- (3-amino-1-pyridin-4-yl-1H-isoindol-1-yl) phenyl] thiophene-2-carbaldehyde; 1- [3- (1-isobutyl-1H-pyrazol-4-yl) phenyl] -1-pyridin-4-yl-1H-isoindol-3-amine 0.25 acetate; 1- [3- (5-methyl-2-furyl) phenyl] -1-pyridin-4-yl-1H-isoindol-3-amine acetate; 3 '- (3-amino-1-pyridin-4-yl-1H-isoindol-1-yl) biphenyl-2-carboxamide 0.25 acetate; 4- {3-amino-1- [3- (2-fluoropyridin-3-yl) phenyl] -1H-isoindol-1-yl} benzonitrile; 1- [3- (2-fluoropyridin-3-yl) phenyl] -1- [4- (trifluoromethyl) phenyl] -1H-isoindol-3-amine; 1- [3- (5-fluoropyridin-3-yl) phenyl] -1-pyridin-4-yl-1H-isoindol-3-amine 0.75 acetate; 1- (4-fluoro-3-pyrimidin-5-yl-phenyl) -1-pyridin-4-yl-1H-isoindol-3-amine 0.5 acetate; 1- [4-fluoro-3- (5-fluoropyridin-3-yl) phenyl] -1-pyridin-4-yl-1H-isoindol-3-amine 0.75 acetate; 1- (3-fluoropyridin-4-yl) -1- [3- (5-fluoropyridin-3-yl) phenyl] -1H-isoindol-3-amine 0.5 acetate; 1- (3-fluoropyridin-4-yl) -1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine 1.25 acetate; 1- (3-fluoropyridin-4-yl) -1- [3- (2-fluoropyridin-3-yl) phenyl] -1H-isoindol-3-amine 1.25 acetate; 1- (3-fluoropyridin-4-yl) -1- (4-fluoro-3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine 1.25 acetate; 1- [4-fluoro-3- (5-fluoropyridin-3-yl) phenyl] -1- (3-fluoropyridin-4-yl) -1H-isoindol-3-amine 1.5 acetate; 1- [4-fluoro-3- (2-fluoropyridin-3-yl) phenyl] -1- (3-fluoropyridin-4-yl) -1H-isoindol-3-amine 1.5 acetate; 5- [3- (3-amino-1-pyridin-4-yl-1H-isoindol-1-yl) phenyl] nicotinonitrile acetate; 6-fluoro-1- (4-methoxyphenyl) -1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine; 6-fluoro-1- (4-methoxyphenyl) -1- (3-pyridin-3-ylphenyl) -1H-isoindol-3-amine; 6-fluoro-1- (3'-methoxybiphenyl-3-yl) -1- (4-methoxyphenyl) -1H-isoindol-3-amine; 6-fluoro-1- (4-methoxyphenyl) -1- [3- (5-methoxypyridin-3-yl) phenyl] -1H-isoindol-3-amine; 6-fluoro-1-pyridin-4-yl-1- (3-pyridin-3-ylphenyl) -1H-isoindol-3-amine; 6-fluoro-1-pyridin-4-yl-1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine; 6-fluoro-1- [3- (5-methoxypyridin-3-yl) phenyl] -1-pyridin-4-yl-1H-isoindol-3-amine; 6-fluoro-1- [3- (2-fluoropyridin-3-yl) phenyl] -1-pyridin-4-yl-1H-isoindol-3-amine; 1- (3 ', 5'-dichlorobiphenyl-3-yl) -1- (4-methoxyphenyl) -1H-isoindol-3-amine acetate; 3 '- (3-amino-1-cyclopropyl-1H-isoindol-1-yl) -5-methoxybiphenyl-2-carbonitrile acetate; 1-cyclopropyl-1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine acetate; 3 '- (3-amino-1-methyl-1H-isoindol-1-yl) -5-methoxybiphenyl-2-carbonitrile acetate; 1- (3 ', 5'-dichlorobiphenyl-3-yl) -1-methyl-1H-isoindol-3-amine hydrochloride; 1-methyl-1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine acetate; 1- [3- (2-fluoropyridin-3-yl) phenyl] -1-methyl-1H-isoindol-3-amine acetate; 1-isopropyl-1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine acetate; and 1- [3- (5-fluoropyridin-3-yl) phenyl] -1-methyl-1H-isoindol-3-amine acetate; in the form of a free base or a pharmaceutically acceptable salt, solvate or solvate thereof. 13. A compound selected from: 1- (2'-fluoro-5'-methoxybiphenyl-3-yl) -1- (3-fluoropyridin-4-yl) -1H-isoindol-3-amine; 1- (2'-fluoro-3'-methoxybiphenyl-3-yl) -1- (3-fluoropyridin-4-yl) -1H-isoindol-3-amine; 1- (2 ', 6-difluoro-3'-methoxybiphenyl-3-yl) -1- (3-fluoropyridin-4-yl) -1H-isoindol-3-amine; 5- {3- [3-amino-1- (3-fluoropyridin-4-yl) -1H-isoindol-1-yl] phenyl} nicotinonitrile; 1- (2'-fluoro-5'-methoxybiphenyl-3-yl) -1-pyridin-4-yl-1H-isoindol-3-amine; 1- (2'-fluoro-3'-methoxybiphenyl-3-yl) -1-pyridin-4-yl-1H-isoindol-3-amine; 1- [4-fluoro-3- (2-fluoropyridin-3-yl) phenyl] -1-pyridin-4-yl-1H-isoindol-3-amine; 1- [3- (2-fluoropyridin-3-yl) phenyl] -1- (2-methoxypyrimidin-5-yl) -1H-isoindol-3-amine; 1- (2-methoxypyrimidin-5-yl) -1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine; 1- (2'-fluoro-3'-methoxybiphenyl-3-yl) -1- (2-methoxypyrimidin-5-yl) -1H-isoindol-3-amine; 1- (2-ethylpyridin-4-yl) -1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine; 1- (2-ethylpyridin-4-yl) -1- [3- (2-fluoropyridin-3-yl) phenyl] -1H-isoindol-3-amine; 1- (2-isopropylpyridin-4-yl) -1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine; 1- [3- (2-fluoropyridin-3-yl) phenyl] -1- (2-isopropylpyridin-4-yl) -1H-isoindol-3-amine; 1- (2-fluoropyridin-4-yl) -1- [3- (2-fluoropyridin-3-yl) phenyl] -1H-isoindol-3-amine; 1- [3- (2-fluoropyridin-3-yl) phenyl] -1- (2-methoxypyridin-4-yl) -1H-isoindol-3-amine; 1- (2-chloropyridin-4-yl) -1- [3- (2-fluoropyridin-3-yl) phenyl] -1H-isoindol-3-amine; 1- (2-chloropyridin-4-yl) -1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine; 1- (5-fluoropyridin-3-yl) -1- [3- (2-fluoropyridin-3-yl) phenyl] -1H-isoindol-3-amine; 1- (5-fluoropyridin-3-yl) -1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine; 1- (4-fluoro-3-pyrimidin-5-ylphenyl) -1- (4-methoxy-3-methylphenyl) -1H-isoindol-3-amine; 1- [4-fluoro-3- (2-fluoropyridin-3-yl) phenyl] -1- (4-methoxy-3-methylphenyl) -1H-isoindol-3-amine; 6-chloro-1-pyridin-4-yl-1- (3-pyrimidin-5-ylphenyl) -1H-isoindol-3-amine; 1- (3-pyrimidin-5-ylphenyl) -1- [6- (trifluoromethyl) pyridin-3-yl] -1H-isoindol-3-amine 0.66 acetate; 3- [3-amino-1- (2,6-dichloropyridin-4-yl) -1H-isoindol-1-yl] phenyl-5-chloro-1,3-dimethyl-1H-pyrazole-4-sulfonate; 3- [3-amino-1- (2,6-dichloropyridin-4-yl) -1H-isoindol-1-yl] phenyl-6-chlorimidazo [2,1-b] [1,3] thiazol-5- sulfonate; 3- [3-amino-1- (2,6-dichloropyridin-4-yl) -1H-isoindol-1-yl] phenyl-2,6-difluorobenzenesulfonate; 3- [3-amino-1- (4-fluoro-3-pyrimidin-5-ylphenyl) -1H-isoindol-1-yl] phenyl trifluoromethanesulfonate; 3- [3-amino-1- (4-fluoro-3-pyrimidin-5-ylphenyl) -1H-isoindol-1-yl] phenyl trifluoromethanesulfonate; and 4- [3-amino-1- (4-fluoro-3-pyrimidin-5-ylphenyl) -1H-isoindol-1-yl] phenyl trifluoromethanesulfonate; in the form of a free base or a pharmaceutically acceptable salt, solvate or solvate thereof. 14. The compound according to claim 1 for use in therapy. 15. A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of a compound according to any one of claims 1 to 13, together with pharmaceutically acceptable excipients, carriers or diluents. 16. The use of a compound according to any one of claims 1 to 13 as a medicine. 17. The use of a compound according to any one of claims 1 to 13 as a medicine for the treatment or prevention of Aβ (β-amyloid protein) -associated pathology. 18. The use of a compound according to any one of claims 1 to 13 as a medicament for the treatment or prevention of Aβ-associated pathology, wherein said Aβ-associated pathology is Down syndrome, β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorder associated with cognitive impairment, MCI ("moderate cognitive impairment"), Alzheimer's disease, memory loss, symptoms of attention deficit associated with Alzheimer's disease, neurodegeneration, ssotsiirovannuyu with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, predsenilnuyu dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy and corticobasal degeneration. 19. The use of a compound according to any one of claims 1 to 13 in the manufacture of a medicament for the treatment or prevention of Aβ-associated pathology. 20. The use of a compound according to any one of claims 1 to 13 in the manufacture of a medicament for the treatment or prevention of Aβ-associated pathology, wherein said Aβ-associated pathology is Down syndrome, β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorder associated with cognitive impairment, MCI ("moderate cognitive impairment"), Alzheimer's disease, memory loss, symptoms of attention deficit associated with Alzheimer's disease, neurodegenerator uw associated with Alzheimer's disease, dementia of mixed vascular origin, dementia of degenerative origin, dementia predsenilnuyu, senile dementia dementia associated with Parkinson's disease, progressive supranuclear palsy and corticobasal degeneration. 21. A method for inhibiting BACE activity (an enzyme that cleaves the beta site of an amyloid beta precursor protein) comprising contacting said BACE with a compound according to any one of claims 1 to 13. 22. A method of treating or preventing an Aβ-associated pathology in a mammal, comprising administering to said patient a therapeutically effective amount of a compound according to any one of claims 1 to 13. 23. The method of claim 22, wherein said Aβ-associated pathology is Down syndrome, β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer's disease , memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, mixed vascular dementia, degenerative dementia Niya, predsenilnuyu dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy and corticobasal degeneration. 24. The method of claim 22, wherein said mammal is a human. 25. A method of treating or preventing an Aβ-associated pathology in a mammal, comprising administering to a specified patient a therapeutically effective amount of a compound according to any one of claims 1 to 13 and at least one cognitive function improving agent, memory improving agent, or cholinesterase inhibitor. 26. The method according A.25, where the specified Aβ-associated pathology is Down syndrome, β-amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("moderate cognitive impairment"), Alzheimer's disease , memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with Alzheimer's disease, mixed vascular dementia, degenerative dementia Niya, predsenilnuyu dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy and corticobasal degeneration. 27. The method according A.25, where the specified mammal is a human.